Sickle Cell Disease – Access & Reimbursement – Detailed, Expanded Analysis (US)
Sickle cell disease (SCD) is a rare genetic blood disorder characterized by polymerization of hemoglobin in red blood cells that distorts them into a sickle shape. This sickling leads to various complications, including painful VOCs. While hydroxyurea—often in combination with prophylactic penicillin, analgesics, and/or blood transfusions—has been the standard of care for SCD, the FDA’s approval of Emmaus Life Sciences’ Endari (L-glutamine), Global Blood Therapeutics / Pfizer’s Oxbryta (voxelotor), and Novartis’s Adakveo (crizanlizumab) has provided patients with targeted treatment options. Moreover, gene therapies from Bluebird Bio (lovotibeglogene autotemcel [lovo-cel]) and Vertex / CRISPR Therapeutics (exagamglogene autotemcel [exa-cel]) are on the horizon, offering curative potential for SCD. Additionally, two emerging symptomatic therapies—inclacumab, a human MAb P-selectin inhibitor, and GBT021601, a next-generation hemoglobin S polymerization inhibitor, both from Global Blood Therapeutics / Pfizer—are likely to be efficacious targeted symptomatic treatments for SCD patients. This report explores the views and policies that physicians and payers have regarding approved SCD therapies and assesses hematologists’ expectations for and potential usage patterns of emerging gene and symptomatic therapies in the context of payers’ receptivity to and potential market access decisions regarding such treatments.
QUESTIONS ANSWERED
- What is the current state of coverage of therapies approved to treat SCD in the United States? What restrictions do payers impose, and how do market access dynamics influence surveyed hematologists’ prescribing?
- What kinds of price concessions and clinical data do payers want to see to favorably cover the emerging gene therapies lovo-cel and exa-cel and the emerging symptomatic therapies inclacumab and GBT021601 for SCD?
- How receptive are physicians to emerging gene and symptomatic therapies for SCD? What clinical and nonclinical factors will drive the use of these therapies, and what payer controls will constrain their prescribing of these therapies?
CONTENT HIGHLIGHTS
Geography: United States
Primary Research: Survey of 100 U.S. hematologists. Survey of 31 U.S. managed care organization (MCO) pharmacy and medical directors (PDs/MDs).
Key Drugs Covered: Adakveo (crizanlizumab), Endari (L-glutamine), Oxbryta (voxelotor), lovotibeglogene autotemcel (lovo-cel), exagamglogene autotemcel (exa-cel), inclacumab, GBT021601.
PRODUCT DESCRIPTION
U.S. Access & Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment. Each report includes up-to-date analyses of drug coverage and restriction policies as well as payer and prescriber perspectives on key marketed drugs and their receptivity to emerging therapies.
Sukhvinder Singh, M.Tech., is a senior analyst on the Infectious, Niche, and Rare Diseases team at Clarivate. He has several years of experience providing research and analytics support in the pharmaceutical domain. He has worked in numerous therapy areas, including ophthalmology, dermatology, neurology, and rare diseases. Prior to joining Clarivate, Mr. Singh was an assistant project manager on the forecasting and analytics team at DelveInsight Business Research. He was responsible for preparing epidemiology and market research reports, which included pipeline assessments, sales forecasting, and commercial opportunity assessments. He earned his master’s degree in technology and biotechnology at Amity University in Noida, India.